Provided is a dried powder of microorganisms, which is highly suitable for processing and has excellent usefulness as one component of various products. The present invention provides: a dried powder of microorganisms, the dried powder exhibiting a brightness of 55 or more and a chromaticness of 18 or less; and a method for producing a dried powder of microorganisms, the method comprising: washing microorganisms at least once with a liquid having an osmotic pressure lower than that of a liquid culture medium for culturing the microorganisms; and drying and heating the microorganisms after the washing to thereby obtain the dried powder of the microorganisms, which exhibits a brightness of 55 or more and a chromaticness of 18 or less.

A relatively fast, inexpensive, and non-destructive method for separation and isolation of biologically active nanoparticles is described. Methods include the use of solid phase separation medis such as channeled fibers in a hydrophobic interaction chromatography (HIC) protocol to isolate biologically active nanoparticles from other components of a mixture. Biologically active nanoparticles can include natural nanoparticles (e.g., exosomes, lysosomes, virus particles) as well as synthetic nanoparticles (liposomes, genetically modified virus particles, etc.)

Quorum-sensing peptides are provided as diagnostic biomarkers, and quorum-sensing peptide inhibiting substances are provided for use in the treatment of metastasis of colorectal cancer in a subject, in particular a human subject. Methods for reducing metastasis of colorectal cancer in a subject include administering to the subject a microorganism that reduces or blocks activity of a pro-metastatic quorum-sensing peptide or a metabolite thereof present in a gastrointestinal tract or blood of the subject; and/or that reduces or blocks production of the pro-metastatic quorum-sensing peptide or the metabolite thereof in the gastrointestinal tract or blood of the subject. The pro-metastatic quorum-sensing peptide may include EntF or the metabolite EntF* of EntF.

A drug for preventing and/or treating a brain tumor and an application thereof. The drug comprises Plasmodium. The drug has significant preventive and/or therapeutic effects on a brain tumor, and is capable of inhibiting the growth of the brain tumor and prolonging the life span of a patient, and has no obvious side effects and has a high safety level. The drug expands treatment methods for brain tumors. Due to the specificity and sensitivity of brain tissues, chemotherapeutic drugs cannot easily cross the blood-brain barrier and exert anti-tumor effects. The drug mainly regulates the immunological functions and inflammation-related factors of the body to break through the blood-brain barrier by fully activating immunocompetence and inhibiting the growth of a brain tumor, thereby extending lifespan.

A drug for preventing and/or treating a brain tumor and an application thereof. The drug comprises Plasmodium. The drug has significant preventive and/or therapeutic effects on a brain tumor, and is capable of inhibiting the growth of the brain tumor and prolonging the life span of a patient, and has no obvious side effects and has a high safety level. The drug expands treatment methods for brain tumors. Due to the specificity and sensitivity of brain tissues, chemotherapeutic drugs cannot easily cross the blood-brain barrier and exert anti-tumor effects. The drug mainly regulates the immunological functions and inflammation-related factors of the body to break through the blood-brain barrier by fully activating immunocompetence and inhibiting the growth of a brain tumor, thereby extending lifespan.

A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.

A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.

A relatively fast, inexpensive, and non-destructive method for separation and isolation of biologically active nanoparticles is described. Methods include the use of solid phase separation medis such as channeled fibers in a hydrophobic interaction chromatography (HIC) protocol to isolate biologically active nanoparticles from other components of a mixture. Biologically active nanoparticles can include natural nanoparticles (e.g., exosomes, lysosomes, virus particles) as well as synthetic nanoparticles (liposomes, genetically modified virus particles, etc.)

Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.

Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.